SEC Form SC 13G filed by Aprea Therapeutics Inc.

$APRE
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $APRE alert in real time by email
SC 13G 1 formsc13g.htm

 

 

 

UNITED STATE

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

 

  ApreaTherapeutics, Inc.  
  (Name of Issuer)  
     
 

Common Stock, $0.001 par value per share 

 
  (Title of Class of Securities)  
     
  03836J102  
  (CUSIP Number)  
     
  February 23, 2023  
  (Date of Event Which Requires Filing of this Statement)  

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed

 

Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)

 

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. 03836J102

 

1.

Names of Reporting Persons. AIGH Capital Management, LLC

I.R.S. Identification Nos. of above persons (entities only).

 

27-4413262

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) ☐

(b) ☒

3.

SEC Use Only

 

4.

Citizenship of Place of Organization

 

Maryland

Number of Shares

Beneficially

Owned by Each

Reporting Person

With

5.

Sole Voting Power

 

345,000

6.

Shared Voting Power

 

0

7.

Sole Dispositive Power

 

345,000

8.

Shared Dispositive Power

 

 

9.

Aggregate Amount Beneficially Owned by each Reporting Person

 

345,000

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐

 

 

11.

Percent of Class Represented by Amount in Row 9

 

9.2%

12.

Type of Reporting Person (See Instructions)

 

OO

 

 

 

 

CUSIP No. 03836J102

 

1.

Names of Reporting Persons. Orin Hirschman

I.R.S. Identification Nos. of above persons (entities only).

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) ☐

(b) ☒

3.

SEC Use Only

 

4.

Citizenship of Place of Organization

 

United States

Number of Shares

Beneficially

Owned by Each

Reporting Person

With

5.

Sole Voting Power

 

345,000

6.

Shared Voting Power

 

 

7.

Sole Dispositive Power

 

345,000

8.

Shared Dispositive Power

 

 

9.

Aggregate Amount Beneficially Owned by each Reporting Person

 

345,000

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐

 

 

11.

Percent of Class Represented by Amount in Row 9

 

9.2

12.

Type of Reporting Person (See Instructions)

 

IN

 

 

 

 

ITEM 1:

 

(a) Name of Issuer:

 

Aprea Therapeutics, Inc.

 

(b) Address of Issuer’s Principal Executive Offices:

 

535 Boylston Street

Boston, Massachusetts 02116

 

ITEM 2:

 

(a) Name of Person Filing:

 

This Schedule 13G is being jointly filed by each of the following persons pursuant to Rule 13d-1 promulgated by the Securities and Exchange Commission pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the “Act”):

 

(i) AIGH Capital Management, LLC, a Maryland limited liability company (“AIGH CM”), as an Advisor or Sub-Advisor with respect to shares of Common Stock (as defined in Item 2(d) below) held by AIGH Investment Partners, L.P., WVP Emerging Manger Onshore Fund, LLC – AIGH Series, and WVP Emerging Manger Onshore Fund, LLC- Optimized Equity Series;
   
(ii)

AIGH Investment Partners, L.L.C., a Delaware limited liability company (“AIGH LLC”), with respect to shares of Common Stock (as defined in Item 2(d) below) directly held by it;

   
(iii) Mr. Orin Hirschman (“Mr. Hirschman”), who is the Managing Member of AIGH Capital Management, LLC and president of AIGH LLC, with respect to shares of Common Stock (as defined in Item 2(d) below) indirectly held through AIGH CM, directly by AIGH LLC and Mr. Hirschman and his family directly.

 

AIGH Capital Management LLC., AIGH Investment Partners LLC, and Mr. Hirschman are hereinafter sometimes collectively referred to as the “Reporting Persons.” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

 

(b) Address of Principal Business Office or, if None, Residence:

 

The principal office and business address of AIGH Capital Management LLC, AIGH Investment Partners LLC, and Mr. Hirschman is:

 

6006 Berkeley Avenue

Baltimore MD 21209

 

(c) Citizenship:

 

See Item 2(a) above and Item 4 of each cover page.

 

(d) Title of Class of Securities:

 

Common Stock, $0.001 par value per share

 

(e) CUSIP Number:

 

03836J102

 

 

 

 

ITEM 3: IF THIS STATEMENT IS FILED PURSUANT TO §§240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

 

  (a) ☐  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
       
  (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
       
  (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
       
  (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
       
  (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
       
  (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
       
  (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
       
  (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       
  (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
       
  (j) A non-U.S. institution, in accordance with §240.13d-1(b)(1)(ii)(J);
       
  (k) Group, in accordance with §240.13d-1(b)(1)(ii)(K).
     

 

If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ___________________________.

 

ITEM 4: OWNERSHIP.

 

See Item s 5,6,7,8 and 9 of each cover page.

 

ITEM 5: OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐

 

ITEM 6: OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

 

Not applicable.

 

ITEM 7: IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

 

Not applicable.

 

ITEM 8: IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

 

Not applicable.

 

ITEM 9: NOTICE OF DISSOLUTION OF GROUP.

 

Not applicable.

 

ITEM 10: CERTIFICATIONS.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: March 3, 2023 By: /s/ Orin Hirschman
    Orin Hirschman,
    Individually and as (a) managing member of AIGH Capital Management LLC.: and (b) president of AIGH Investment Partners LLC.

 

 

 

Get the next $APRE alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$APRE

DatePrice TargetRatingAnalyst
8/20/2021Neutral → Underweight
JP Morgan
8/16/2021Buy → Hold
Berenberg
8/16/2021$6.00 → $4.00Neutral
HC Wainwright & Co.
8/13/2021$6.00 → $5.00Sector Perform
RBC Capital
8/13/2021$5.00 → $3.00Equal-Weight → Underweight
Morgan Stanley
More analyst ratings

$APRE
Press Releases

Fastest customizable press release news feed in the world

See more
  • Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

    ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 Twice daily (BID) dosing regimen in ongoing ABOYA-119 trial expected to maximize clinical benefit of ATR inhibitor ATRN-119; plan to complete dose escalation H2 2025 $22.8 million in cash and cash equivalents as of December 31, 2024 DOYLESTOWN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today reported financial

    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

    DOYLESTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, announced today that it has entered into a Material Transfer Agreement (MTA) with MD Anderson Cancer Center. Under the agreement, Aprea will supply its proprietary WEE1 kinase inhibitor, APR-1051, to support preclinical research aimed at exploring its potential in treating HPV+ and HPV- head and neck squamous cell carcinoma (HNSCC) expressing genomic markers of replication stress. The agreement will enable

    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

    DOYLESTOWN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today provided an update on its existing patent portfolio. "Our strong patent portfolio reflects our commitment to innovation and leadership in the field of DNA Damage Response therapeutics," said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. "Intellectual property is an essential component of Aprea's strategy, enabling us to advance first in class and best in class oncology treatments

    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

$APRE
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$APRE
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$APRE
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$APRE
SEC Filings

See more

$APRE
Leadership Updates

Live Leadership Updates

See more
  • Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

    DOYLESTOWN, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has engaged Philippe Pultar, MD as its senior medical advisor to support Aprea with developing and advancing APR-1051, Aprea's potential best in class WEE1 inhibitor. Dr. Pultar is a seasoned pharmaceutical executive with extensive experience in oncology, including the development of a WEE1 inhibitor (azenosertib) from early to late-stage clinical development. Dr. Pultar has vast experience in clinical development within both large and early-stag

    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer

    Brings proven leadership and successful track record to Halda as the company enters the next stage of growth as clinical-stage company Halda Therapeutics, a biotechnology company developing a novel class of cancer therapies called RIPTAC™ (Regulated Induced Proximity TArgeting Chimeras) therapeutics, today announced that it has appointed Christian Schade as President and Chief Executive Officer and a member of the Board of Directors. Chris brings more than 20 years of public and private pharmaceutical and biotechnology industry experience, including building, financing and leading biotechnology companies through the clinical stages of pipeline development and formation of value-creating de

    $APRE
    $IART
    $OMGA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: Biological Products (No Diagnostic Substances)
  • Alltrna Announces Updates to Its Board of Directors

    Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

    $APRE
    $CYTK
    $EVLO
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: Biological Products (No Diagnostic Substances)

$APRE
Financials

Live finance-specific insights

See more
  • Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations

    BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial results for the three and six months ended June 30, 2022 and provided a business update. "This is an exciting time for Aprea as we advance our ATR program into clinical development this year, continue to progress our WEE1 program toward IND submission and leverage our unique discovery platform capabilities to build for future success," said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. "We believe o

    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results

    BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways today announced that it has acquired Atrin Pharmaceuticals Inc. ("Atrin") and reported financial results for the three months ended March 31, 2022. Business Operations Update:  On May 16, 2022 Aprea completed the acquisition of Atrin, a privately held biotechnology company focused on the discovery and development of novel therapeutics targeting proteins in the DNA damage response, or DDR, pathway in oncology through synthetic lethality. The Company believes its cash and cash

    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs

    BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its clinical trials of eprenetapopt in combination with azacitidine in its myeloid malignancy programs. The partial clinical hold does not apply to the Company's ongoing clinical trials in lymphoid malignancies and solid tumors, or the APR-548 clinical trial. There are approximately 20 patients currently receiving eprenetapopt in combination with azacitidine i

    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

$APRE
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more